Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
14:07 ET -- Merck is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. After the bell Thursday, Merck and Daiichi Sankyo announced a global development and commercialization collaboration for three Daiichi Sankyo DXd ADCs. On Friday, Merck released data showing its Keytruda in combination with other treatments showed statistically significant improvement in pathological complete response rate for certain breast cancer patients, and that it improved progression-free survival in certain patients with cervical cancer. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
October 20, 2023 14:22 ET (18:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth